Cantor Fitzgerald Comments on Septerna FY2025 Earnings

Septerna, Inc. (NASDAQ:SEPN) – Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Septerna in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post earnings per share of ($2.58) for the year. Cantor Fitzgerald has a “Overweight” rating and a $50.00 price objective on the stock. The consensus estimate for Septerna’s current full-year earnings is ($7.11) per share.

Several other research firms have also recently weighed in on SEPN. Wells Fargo & Company started coverage on Septerna in a report on Tuesday, November 19th. They set an “overweight” rating and a $43.00 price objective on the stock. JPMorgan Chase & Co. assumed coverage on shares of Septerna in a report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 target price on the stock. Finally, TD Cowen started coverage on Septerna in a research note on Tuesday, November 19th. They issued a “buy” rating on the stock.

Septerna Price Performance

Shares of Septerna stock opened at $19.38 on Thursday. Septerna has a 52 week low of $15.86 and a 52 week high of $28.99. The company’s fifty day simple moving average is $22.49.

Hedge Funds Weigh In On Septerna

A hedge fund recently bought a new stake in Septerna stock. SG Americas Securities LLC acquired a new stake in shares of Septerna, Inc. (NASDAQ:SEPN) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 8,095 shares of the company’s stock, valued at approximately $185,000.

Insider Transactions at Septerna

In related news, major shareholder Rock Ventures V. L.P. Third bought 370,500 shares of the company’s stock in a transaction on Monday, October 28th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $6,669,000.00. Following the completion of the purchase, the insider now directly owns 6,215,591 shares in the company, valued at $111,880,638. The trade was a 6.34 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.